ASCO 2014: Lilly's necitumumab fails to impress with SQUIRE
This article was originally published in Scrip
Executive Summary
Eli Lilly is to file its recombinant human IgG1 monoclonal antibody against epidermal growth factor receptor 1 (EGFR 1) necitumumab by the end of the year, based on the Phase III SQUIRE study newly presented at ASCO. However, detailed analysis of the results from the largest study to date in the first-line treatment of stage IV squamous non-small cell lung cancer has left analysts unimpressed by its marginal benefits.